Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

NCT03363035 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2055

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome
Myocardial Infarction
Myocardial Ischemia
Unstable Angina

Interventions

DRUG: Rivaroxaban 2.5 mg
DRUG: Rivaroxaban 5 mg
DRUG: Enoxaparin

Sponsor

Second Xiangya Hospital of Central South University